Thierry Roumeguère

Thierry Roumeguère

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001 in European Urology
Verified
Journal Article
Closed access
PDF file
RBR. Bollens
R. Bollens
MBM. Vanden Bossche
M. Vanden Bossche
TRThierry Roumeguère
Thierry Roumeguère
ADA. Damoun
A. Damoun
SES. Ekane
S. Ekane
CSC.C. Schulman
C.C. Schulman
Introduction: After an initial experience using transperitoneal laparoscopic radical prostatectomy as described by Vallancien and Guillonneau, we developed a pure extraperitoneal ap

1 September 2003 in European Urology
Verified
Journal Article
Closed access
TRThierry Roumeguère
Thierry Roumeguère
EWE Wespes
E Wespes
YCY Carpentier
Y Carpentier
PHP Hoffmann
P Hoffmann
CSC.C Schulman
C.C Schulman

1 May 2003 in World Journal of Urology
Verified
Journal Article
Closed access
TRThierry Roumeguère
Thierry Roumeguère
RBRenaud Bollens
Renaud Bollens
MBMarc Vanden Bossche
Marc Vanden Bossche
DRDan Rochet
Dan Rochet
DBDavid Bialek
David Bialek
AZAlexandre R. Zlotta
Alexandre R. Zlotta

1 November 2005 in European Urology
Verified
Journal Article
Closed access
TRThierry Roumeguère
Thierry Roumeguère
TQT Quackels
T Quackels
RBR Bollens
R Bollens
ADA Degroote
A Degroote
AZA Zlotta
A Zlotta
CSC Schulman
C Schulman

1 March 2008 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
ALAnne Lemy
Anne Lemy
KWKarl M. Wissing
Karl M. Wissing
SRSandrine Rorive
Sandrine Rorive
AZAlexandre Zlotta
Alexandre Zlotta
TRThierry Roumeguère
Thierry Roumeguère
JNJoëlle Nortier
Joëlle Nortier

24 July 2013 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
CDCedric Delporte
Cedric Delporte
PAPierre Van Antwerpen
Pierre Van Antwerpen
LVLuc Vanhamme
Luc Vanhamme
TRThierry Roumeguère
Thierry Roumeguère
KBKarim Zouaoui Boudjeltia
Karim Zouaoui Boudjeltia
Oxidation of low-density lipoprotein (LDL) has a key role in atherogenesis. Among the different models of oxidation that have been studied, the one using myeloperoxidase (MPO) is thought to be more physiopathologically relevant. Apolipoprotein B-100 is the unique protein of LDL and is the major target of MPO. Furthermore, MPO rapidly adsorbs at the surface of LDL, promoting oxidation of amino acid residues and formation of oxidized lipoproteins that are commonly named Mox-LDL. The latter is not recognized by the LDL receptor and is accumulated by macrophages. In the context of atherogenesis, Mox-LDL accumulates in macrophages leading to foam cell formation. Furthermore, Mox-LDL seems to have specific effects and triggers inflammation. Indeed, those oxidized lipoproteins activate endothelial cells and monocytes/macrophages and induce proinflammatory molecules such as TNFαand IL-8. Mox-LDL may also inhibit fibrinolysis mediated via endothelial cells and consecutively increase the risk of thrombus formation. Finally, Mox-LDL has been involved in the physiopathology of several diseases linked to atherosclerosis such as kidney failure and consequent hemodialysis therapy, erectile dysfunction, and sleep restriction. All these issues show that the investigations of MPO-dependent LDL oxidation are of importance to better understand the inflammatory context of atherosclerosis.